FR2600255B1 - Substituant acellulaire des hematies - Google Patents

Substituant acellulaire des hematies

Info

Publication number
FR2600255B1
FR2600255B1 FR878708639A FR8708639A FR2600255B1 FR 2600255 B1 FR2600255 B1 FR 2600255B1 FR 878708639 A FR878708639 A FR 878708639A FR 8708639 A FR8708639 A FR 8708639A FR 2600255 B1 FR2600255 B1 FR 2600255B1
Authority
FR
France
Prior art keywords
hematies
acellular
substitute
acellular substitute
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR878708639A
Other languages
English (en)
Other versions
FR2600255A1 (fr
Inventor
Lakshman R Sehgal
Richard E Dewoskin
Gerald S Moss
Steven A Gould
Arthur L Rosen
Hansa Sehgal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NORTHFIELD LAB
Northfield Laboratories Inc
Original Assignee
NORTHFIELD LAB
Northfield Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NORTHFIELD LAB, Northfield Laboratories Inc filed Critical NORTHFIELD LAB
Publication of FR2600255A1 publication Critical patent/FR2600255A1/fr
Application granted granted Critical
Publication of FR2600255B1 publication Critical patent/FR2600255B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
    • C08H1/00—Macromolecular products derived from proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR878708639A 1986-06-20 1987-06-19 Substituant acellulaire des hematies Expired - Lifetime FR2600255B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/876,689 US4826811A (en) 1986-06-20 1986-06-20 Acellular red blood cell substitute

Publications (2)

Publication Number Publication Date
FR2600255A1 FR2600255A1 (fr) 1987-12-24
FR2600255B1 true FR2600255B1 (fr) 1990-07-27

Family

ID=25368368

Family Applications (1)

Application Number Title Priority Date Filing Date
FR878708639A Expired - Lifetime FR2600255B1 (fr) 1986-06-20 1987-06-19 Substituant acellulaire des hematies

Country Status (11)

Country Link
US (1) US4826811A (fr)
EP (1) EP0271542B1 (fr)
JP (1) JP2983544B2 (fr)
CA (1) CA1298783C (fr)
DE (2) DE3790322T1 (fr)
FR (1) FR2600255B1 (fr)
GB (2) GB8801735D0 (fr)
IL (1) IL82890A0 (fr)
NL (1) NL194909C (fr)
PT (1) PT85133B (fr)
WO (1) WO1987007832A1 (fr)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464814A (en) * 1986-06-20 1995-11-07 Northfield Laboratories, Inc. Acellular red blood cell substitute
US5194590A (en) * 1986-06-20 1993-03-16 Northfield Laboratories, Inc. Acellular red blood cell substitute
CA1312009C (fr) * 1986-11-10 1992-12-29 Carl W. Rausch Substitut sanguin semi-synthetique extra pur
US5084558A (en) * 1987-10-13 1992-01-28 Biopure Corporation Extra pure semi-synthetic blood substitute
US5753616A (en) * 1986-11-10 1998-05-19 Biopure Corporation Method for producing a stable polymerized hemoglobin blood-substitute
US5955581A (en) * 1986-11-10 1999-09-21 Biopure Corporation Method for producing a stable polymerized hemoglobin blood-substitute
US5854209A (en) * 1995-03-23 1998-12-29 Biopure Corporation Method for oxygenating tissue having reduced red blood cell flow
US5449759A (en) * 1987-05-16 1995-09-12 Somatogen, Inc. Hemoglobins with intersubunit desulfide bonds
US6022849A (en) * 1987-05-16 2000-02-08 Baxter Biotech Technology Saarl Mutant recombinant hemoglobins containing heme pocket mutations
GB8711614D0 (en) * 1987-05-16 1987-06-24 Medical Res Council Proteins
DE3888199T2 (de) * 1987-12-03 1994-06-09 Chloride Silent Power Ltd Alkalimetallzelle.
US6204009B1 (en) 1988-05-16 2001-03-20 BAXTER BIOTECH TECHNOLOGY SàRL Nucleic acids encoding mutant recombinant hemoglobins containing heme pocket mutations
IL87707A (en) * 1988-09-08 1994-06-24 Technion Inst For Research And Hemoglobin-based blood substitute substantially similar to human blood and method for preparation thereof
IL87708A (en) * 1988-09-08 1994-04-12 Technion Inst For Research And Hemoglobin-based blood substitute possessing a colloid oncotic pressure substantially similar to human blood and method for the preparation thereof
US5545727A (en) * 1989-05-10 1996-08-13 Somatogen, Inc. DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin
NL8901174A (nl) * 1989-05-10 1990-12-03 Het Hoofd Van De Afdeling Mili Hemoglobine-preparaat en gebruik daarvan.
US5439882A (en) * 1989-12-29 1995-08-08 Texas Tech University Health Sciences Center Blood substitute
AU9067791A (en) * 1990-11-20 1992-06-11 Enzon, Inc. Method of enhancing long-term storage stability of hemoglobin products
HUT64571A (en) * 1990-11-29 1994-01-28 Upjohn Co A method for producing hemoglobin preparatives containing imido ester cross bind
AU665599B2 (en) * 1991-11-08 1996-01-11 Hemosol Inc. Hemoglobins as drug delivery agents
US5334706A (en) * 1992-01-30 1994-08-02 Baxter International Administration of low dose hemoglobin to increase perfusion
US5900477A (en) * 1992-01-30 1999-05-04 Baxter International, Inc. Use of hemoglobin in the treatment of hemorrhagic shock
US5980954A (en) 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
US6669965B2 (en) 1992-02-07 2003-12-30 Vasogen Ireland Limited Method of treating atherosclerosis
GB9617611D0 (en) * 1996-08-22 1996-10-02 Vasogen Inc Treatment of autoimmune disease
US5591457A (en) * 1992-02-07 1997-01-07 Vasogen Inc Method of inhibiting the aggregation of blood platelets and stimulating the immune systems of a human
US5646252A (en) * 1992-02-10 1997-07-08 Staat Der Nederlanden, De Minister Van Defensie, Voor Deze: Het Hoofd Van De Afdeling Militair Geneeskundig Beleid Hemoglobin composition and preparation thereof
US6187744B1 (en) 1992-03-11 2001-02-13 Michael W. Rooney Methods and compositions for regulating the intravascular flow and oxygenating activity of hemoglobin in a human or animal subject
JPH09500642A (ja) * 1993-07-23 1997-01-21 ジ・アップジョン・カンパニー ヘモグロビンの投与方法
IS4198A (is) * 1993-08-13 1995-02-14 Somatogen, Inc Meðferð vegna aukaverkana sem tengjast gjöf á utanfrumublóðrauða
US5824781A (en) * 1993-08-16 1998-10-20 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5840701A (en) * 1993-08-16 1998-11-24 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5804561A (en) * 1993-08-16 1998-09-08 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5817632A (en) * 1993-08-16 1998-10-06 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5767089A (en) * 1993-08-16 1998-06-16 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
TW381022B (en) * 1993-08-16 2000-02-01 Hsia Jen Chang Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute
US5741893A (en) * 1993-08-16 1998-04-21 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5807831A (en) * 1993-08-16 1998-09-15 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5725839A (en) * 1993-08-16 1998-03-10 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules for ERI or MRI
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
US6242417B1 (en) 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
US6458762B1 (en) 1994-03-28 2002-10-01 Baxter International, Inc. Therapeutic use of hemoglobin for preserving tissue viability and reducing restenosis
DE4418973A1 (de) * 1994-05-31 1995-12-14 Barnikol Wolfgang Verfahren zur Herstellung molekular-einheitlicher hyperpolymerer Hämoglobine
US6610832B1 (en) 1995-03-23 2003-08-26 Biopure Corporation Preserving a hemoglobin blood substitute with a transparent overwrap
US6271351B1 (en) 1995-03-23 2001-08-07 Biopure Corporation Method for preserving a hemoglobin blood substitute
US5895810A (en) * 1995-03-23 1999-04-20 Biopure Corporation Stable polymerized hemoglobin and use thereof
US6288027B1 (en) 1995-03-23 2001-09-11 Biopure Corporation Preserving a hemoglobin blood substitute with a transparent overwrap
JPH10501823A (ja) * 1995-04-10 1998-02-17 バクスター、インターナショナル、インコーポレイテッド クモ膜下出血の治療における架橋ヘモグロビンの使用
US5952470A (en) * 1995-06-07 1999-09-14 Biopure Corporation Method for separating unmodified hemoglobin from cross-linked hemoglobin
US5741894A (en) * 1995-09-22 1998-04-21 Baxter International, Inc. Preparation of pharmaceutical grade hemoglobins by heat treatment in partially oxygenated form
US5733869A (en) * 1995-10-06 1998-03-31 Baxter International, Inc. Therapeutic administration of hemoglobin in cardiac arrest
WO1997019956A1 (fr) * 1995-11-30 1997-06-05 Somatogen, Inc. Methode de regulation de fonctionnalite au cours de la reticulation des hemoglobines
CA2239303A1 (fr) 1995-12-22 1997-07-03 Somatogen, Inc. Globines incluant des domaines de liaison
CN1129608C (zh) * 1996-03-28 2003-12-03 诺思菲尔德试验室公司 制备非细胞血红细胞代用品的方法和仪器
DE69831248T2 (de) * 1997-02-28 2006-04-13 The Regents Of The University Of California, Oakland Verfahren und zusammensetzungen zur optimierung des sauerstofftransportes in zellfreien systemen
US5814601A (en) * 1997-02-28 1998-09-29 The Regents Of The University Of California Methods and compositions for optimization of oxygen transport by cell-free systems
EP0885613A1 (fr) * 1997-06-21 1998-12-23 Roche Diagnostics GmbH Application d'hémoglobine modifiée au traitement d'anémies et préparations mixtes à base d'hémoglobine modifiée et d'érythropoiétine
DE19802321C2 (de) * 1998-01-23 2000-05-11 Fresenius Ag Verfahren und Vorrichtung zur Aufbereitung von intra- oder postoperativen Blutverlusten für die Autotransfusion
CA2391226A1 (fr) 1999-11-12 2001-05-17 Baxter International, Inc. Compositions d'hemoglobine a effets secondaires reduits
US6747132B2 (en) 2000-11-29 2004-06-08 Apex Biosciences, Inc. Methods for the synthesis of a modified hemoglobin solution
US6518010B2 (en) * 2001-02-28 2003-02-11 Biopure Corporation Use of defibrinated blood for manufacture of a hemoglobin-based oxygen carrier
CN100338093C (zh) * 2001-04-18 2007-09-19 北方实验室公司 储存稳定的血红蛋白溶液的柔韧性容器系统
SI1465643T1 (sl) 2002-01-11 2008-06-30 Sangart Inc Postopki in sestavki za transport kisika z visokoafiniteto za kisik
US7271145B2 (en) * 2002-01-11 2007-09-18 Sangart, Inc. Methods and compositions for oxygen transport comprising modified hemoglobin in plasma
US20030153491A1 (en) * 2002-01-11 2003-08-14 Winslow Robert M. Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
US20050164915A1 (en) * 2002-04-01 2005-07-28 Sangart, Inc. Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
WO2003059287A2 (fr) * 2002-01-11 2003-07-24 Sangart, Inc. Procedes et compositions de transport d'oxygene comprenant un transporteur d'oxygene et un cristalloide en solution hypertonique
US7001715B2 (en) * 2002-02-28 2006-02-21 Biopure Corporation Purification of red blood cells by separation and diafiltration
JP3912206B2 (ja) * 2002-07-05 2007-05-09 株式会社日立製作所 筒内直接燃料噴射装置用燃料ポンプ
RU2325924C2 (ru) * 2002-10-03 2008-06-10 Нортфилд Лэборэтериз, Инк. Способ лечения пациентов с массивной потерей крови
US7481998B2 (en) * 2002-12-02 2009-01-27 Biovec, Llc Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
US7179459B2 (en) * 2002-12-02 2007-02-20 Biovec, Llc Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
US7803365B2 (en) * 2002-12-02 2010-09-28 Biovec, Llc Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
US7501114B2 (en) * 2002-12-02 2009-03-10 Biovec, Llc Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
US9388427B2 (en) 2002-12-02 2016-07-12 Biovec, Llc In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
US7135553B2 (en) * 2003-01-29 2006-11-14 Northfield Laboratories, Inc. Polymerized hemoglobin solutions having reduced amounts of tetramer and method for preparing
US7135554B1 (en) 2004-01-27 2006-11-14 Biopure Corporation Method of forming a polymerized hemoglobin solution from stabilized hemoglobin
JP2008511674A (ja) * 2004-08-31 2008-04-17 サンガート， インコーポレイテッド 酸素運搬成分を使用して血流力学的安定性を増強する方法
WO2006108047A2 (fr) * 2005-04-05 2006-10-12 Biopure Corporation Solutions oxygenees d'hemoglobine polymerisee et leurs utilisations pour la visualisation de tissus oxygenated polymerized hemoglobin solutions and their uses for tissue visualization
US20090004159A1 (en) * 2006-01-24 2009-01-01 The Board Of Trustees Of The University Of Illinoi Polymerized Hemoglobin Media and Its Use in Isolation and Transplantation of Islet Cells
US20070196810A1 (en) * 2006-01-24 2007-08-23 Northfield Laboratories Inc. Polymerized Hemoglobin Media and its Use in Isolation and Transplantation of Islet Cells
US7759306B2 (en) * 2006-05-16 2010-07-20 Simoni Jan S Methods of treating acute blood loss
US20080118572A1 (en) * 2006-10-10 2008-05-22 Harold Richard Hellstrom Methods and compositions for reducing the risk of adverse cardiovascular events associated with the administration of artificial blood
US8273857B2 (en) * 2009-09-22 2012-09-25 Jen-Chang Hsia Compositions and methods of use of neurovascular protective multifunctional polynitroxylated pegylated carboxy hemoglobins for transfusion and critical care medicine
WO2014179793A1 (fr) 2013-05-03 2014-11-06 Washington University Composition de succédané de sang et procédé d'utilisation
WO2020080978A2 (fr) * 2018-10-19 2020-04-23 Рахимджан Ахметджанович РОЗИЕВ Procédé de production de substitut sanguin destiné à être utilisé en médecine vétérinaire
CN114146165B (zh) * 2021-12-02 2022-08-12 润方（北京）生物医药研究院有限公司 一种聚合血红蛋白在制备防治呼吸衰竭药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001200A (en) * 1975-02-27 1977-01-04 Alza Corporation Novel polymerized, cross-linked, stromal-free hemoglobin
US4061736A (en) * 1975-02-02 1977-12-06 Alza Corporation Pharmaceutically acceptable intramolecularly cross-linked, stromal-free hemoglobin
US4001401A (en) * 1975-02-02 1977-01-04 Alza Corporation Blood substitute and blood plasma expander comprising polyhemoglobin
US4053590A (en) * 1975-02-27 1977-10-11 Alza Corporation Compositions of matter comprising macromolecular hemoglobin
DE2617822C3 (de) * 1976-04-23 1981-01-08 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Herstellung eines für die intravenöse Injektion geeigneten Hämoglobinpräparates mit erhöhter Sauerstoffabgabe gegenüber Erythrozyten
JPS52154515A (en) * 1976-04-23 1977-12-22 Biotest Serum Institut Gmbh Hemoglobin preparation strengthening oxygen release property
US4136093A (en) * 1976-04-23 1979-01-23 Biotest-Serum-Institut Gmbh Hemoglobin preparation with increased oxygen release
DE3144705C2 (de) * 1981-11-11 1983-12-08 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Herstellung eines lagerstabilen, vernetzten Hämoglobinpräparates mit hoher Sauerstoff-Transportkapazität, sowie das nach diesem Verfahren hergestellte Hämoglobinpräparat
US4529719A (en) * 1983-05-04 1985-07-16 Tye Ross W Modified crosslinked stroma-free tetrameric hemoglobin
DE3412144A1 (de) * 1984-03-31 1985-10-10 Biotest Pharma GmbH, 6000 Frankfurt Verfahren zur herstellung hochgereinigter, stromafreier, hepatitissicherer human- und tierhaemoglobinloesungen

Also Published As

Publication number Publication date
PT85133A (en) 1987-07-01
PT85133B (pt) 1990-03-30
US4826811A (en) 1989-05-02
EP0271542B1 (fr) 1991-09-04
IL82890A0 (en) 1987-12-20
EP0271542A1 (fr) 1988-06-22
JPH01501471A (ja) 1989-05-25
FR2600255A1 (fr) 1987-12-24
DE3790322T1 (fr) 1988-09-15
NL194909B (nl) 2003-03-03
CA1298783C (fr) 1992-04-14
WO1987007832A1 (fr) 1987-12-30
NL8720283A (nl) 1988-05-02
GB2200639B (en) 1990-12-12
GB8801735D0 (en) 1988-03-30
NL194909C (nl) 2003-07-04
DE3790322C2 (de) 1999-09-02
GB2200639A (en) 1988-08-10
JP2983544B2 (ja) 1999-11-29

Similar Documents

Publication Publication Date Title
FR2600255B1 (fr) Substituant acellulaire des hematies
FR2605214B1 (fr) Prothese perihepatique
NO169707C (no) Opprivbar kapsel
DK618387A (da) Fremgangsmaade til sterilisering
DK562585D0 (da) Behandling
TR23424A (tr) 1,2,3,6-tetrahidro-5-nitro-pirimidin tuerevleri
AT380780B (de) Implantat
BR8502017A (pt) Combinacao de sofa-cama beliche
IT8548703A0 (it) Formulazioni oftalmiche comprendenti bromocriptina
DK56486A (da) Laarbensimplantat
AT386518B (de) Zahnersatz
DK325285A (da) Behandlingsmetode
GB8616696D0 (en) Kit of parts
LV10153A (lv) Sastavs seklu dezinfekcijai
TR22560A (tr) Sulfonilguanidinopirimidin tuerevleri
DK375287A (da) Fungicid indeholdende substituerede thienylaminer
IT1231426B (it) Preparazione di polifluoroenolati
DK629387D0 (da) Fremgangsmaade
ATA171086A (de) Implantat
GB8601724D0 (en) Application of tetracyano-quinodimethanes
FR2624987B3 (fr) Montre-bracelet
KR870015692U (ko) 경운기용 힛치
TR22363A (tr) Alkillestirilmis antrakinonlarin aritilmasi
ES296589Y (es) Conjunto parcial de peluca
ES294530Y (es) Reloj